secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2024-10-24T23:59:59+00:00
Accession:  0001437749-24-031957
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.01, 2.03, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar acquires exclusive worldwide license for ALXN-1840 from Alexion; pays $4M cash + equity
--------------------------------------------------------------------------------

- Monopar gets exclusive worldwide license to ALXN-1840 (bis-choline tetrathiomolybdate) for Wilson disease; Phase 3 trial met primary endpoint, but Alexion terminated after Phase 2 results.
- Upfront: $4M cash ($1M at signing, $3M in 90 days) and 387,329 shares (9.9% beneficial ownership); anti-dilution up to 705,015 total shares.
- Future milestones up to $94M plus tiered royalties (low to mid-double digit) on net sales; mid-double digit sublicensing income share until sales.
- Cash was ~$6M as of Sep 30, 2024; near-term expenses <$1M for regulatory package; expects substantial doubt about going concern in upcoming 10-Q.
- ALXN-1840 has Orphan Drug Designation in US and EU; Monopar plans to initiate FDA discussions; regulatory path uncertain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000143774924031957/0001437749-24-031957-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000143774924031957/mnpr20241021_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-031957

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer